Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology

Open Access 23-04-2024 | Osteosarcoma | Research

Exploring the impact of PDGFD in osteosarcoma metastasis through single-cell sequencing analysis

Authors: Yujing Huang, Dongyan Cao, Manxue Zhang, Yue Yang, Gengming Niu, Lina Tang, Zan Shen, Zhichang Zhang, Yueqing Bai, Daliu Min, Aina He

Published in: Cellular Oncology

Login to get access

Abstract

Purpose

The overall survival rate for metastatic osteosarcoma hovers around 20%. Responses to second-line chemotherapy, targeted therapies, and immunotherapies have demonstrated limited efficacy in metastatic osteosarcoma. Our objective is to validate differentially expressed genes and signaling pathways between non-metastatic and metastatic osteosarcoma, employing single-cell RNA sequencing (scRNA-seq) and additional functional investigations. We aim to enhance comprehension of metastatic mechanisms and potentially unveil a therapeutic target.

Methods

scRNA-seq was performed on two primary osteosarcoma lesions (1 non-metastatic and 1 metastatic). Seurat package facilitated dimensionality reduction and cluster identification. Copy number variation (CNV) was predicted using InferCNV. CellChat characterized ligand-receptor-based intercellular communication networks. Differentially expressed genes underwent GO function enrichment analysis and GSEA. Validation was achieved through the GSE152048 dataset, which identified PDGFD-PDGFRB as a common ligand-receptor pair with significant contribution. Immunohistochemistry assessed PDGFD and PDGFRB expression, while multicolor immunofluorescence and flow cytometry provided insight into spatial relationships and the tumor immune microenvironment. Kaplan-Meier survival analysis compared metastasis-free survival and overall survival between high and low levels of PDGFD and PDGFRB. Manipulation of PDGFD expression in primary osteosarcoma cells examined invasion abilities and related markers.

Results

Ten clusters encompassing osteoblasts, osteoclasts, osteocytes, fibroblasts, pericytes, endothelial cells, myeloid cells, T cells, B cells, and proliferating cells were identified. Osteoblasts, osteoclasts, and osteocytes exhibited heightened CNV levels. Ligand-receptor-based communication networks exposed significant fibroblast crosstalk with other cell types, and the PDGF signaling pathway was activated in non-metastatic osteosarcoma primary lesion. These results were corroborated by the GSE152048 dataset, confirming the prominence of PDGFD-PDGFRB as a common ligand-receptor pair. Immunohistochemistry demonstrated considerably greater PDGFD expression in non-metastatic osteosarcoma tissues and organoids, correlating with extended metastasis-free and overall survival. PDGFRB expression showed no significant variation between non-metastatic and metastatic osteosarcoma, nor strong correlations with survival times. Multicolor immunofluorescence suggested co-localization of PDGFD with PDGFRB. Flow cytometry unveiled a highly immunosuppressive microenvironment in metastatic osteosarcoma. Manipulating PDGFD expression demonstrated altered invasive abilities and marker expressions in primary osteosarcoma cells from both non-metastatic and metastatic lesions.

Conclusions

scRNA-seq illuminated the activation of the PDGF signaling pathway in primary lesion of non-metastatic osteosarcoma. PDGFD displayed an inhibitory effect on osteosarcoma metastasis, likely through the suppression of the EMT signaling pathway.
Appendix
Available only for authorised users
Literature
1.
L. Mirabello, R.J. Troisi, S.A. Savage, Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and end results program. Cancer. 115, 1531–1543 (2009)PubMedCrossRef
2.
H. Koksal, E. Muller, E.M. Inderberg et al., Treating osteosarcoma with CAR T cells. Scand. J. Immunol. 89, e12741 (2019)PubMedCrossRef
3.
M.A. Duggan, W.F. Anderson, S. Altekruse et al., The Surveillance, Epidemiology, and end results (SEER) Program and Pathology: toward strengthening the critical relationship. Am. J. Surg. Pathol. 40, e94–e102 (2016)PubMedPubMedCentralCrossRef
4.
G. Bacci, A. Briccoli, M. Rocca et al., Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann. Oncol. 14, 1126–1134 (2003)PubMedCrossRef
5.
A.M. Goorin, M.B. Harris, M. Bernstein et al., Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J. Clin. Oncol. 20, 426–433 (2002)PubMedCrossRef
6.
W.G. Ward, K. Mikaelian, F. Dorey et al., Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J. Clin. Oncol. 12, 1849–1858 (1994)PubMedCrossRef
7.
J.C. Gentet, M. Brunat-Mentigny, M.C. Demaille et al., Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur. J. Cancer. 33, 232–237 (1997)PubMedCrossRef
8.
F. Navid, J.R. Willert, M.B. McCarville et al., Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 113, 419–425 (2008)PubMedCrossRef
9.
E. Palmerini, R.L. Jones, E. Marchesi et al., Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer. 16, 280 (2016)PubMedPubMedCentralCrossRef
10.
R.L. 3rd Saylors, K.C. Stine, J. Sullivan et al., Cyclophosphamide plus Topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J. Clin. Oncol. 19, 3463–3469 (2001)PubMedCrossRef
11.
P. Van Winkle, A. Angiolillo, M. Krailo et al., Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the children’s Cancer Group (CCG) experience. Pediatr. Blood Cancer. 44, 338–347 (2005)PubMedCrossRef
12.
G. Grignani, E. Palmerini, P. Dileo et al., A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann. Oncol. 23, 508–516 (2012)PubMedCrossRef
13.
G. Grignani, E. Palmerini, V. Ferraresi et al., Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 16, 98–107 (2015)PubMedCrossRef
14.
B. Zhu, J. Li, Q. Xie et al., Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol. Ther. 19, 198–204 (2018)PubMedPubMedCentralCrossRef
15.
H.A. Tawbi, M. Burgess, V. Bolejack et al., Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18, 1493–1501 (2017)PubMedPubMedCentralCrossRef
16.
A. Le Cesne, P. Marec-Berard, J.Y. Blay et al., Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur. J. Cancer. 119, 151–157 (2019)PubMedCrossRef
17.
L. Xie, J. Xu, X. Sun et al., Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J. Immunother Cancer, 8 (2020)
18.
19.
R. Gorlick, P. Anderson, I. Andrulis et al., Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin. Cancer Res. 9, 5442–5453 (2003)PubMed
20.
J. PosthumaDeBoer, M.A. Witlox, G.J. Kaspers et al., Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin. Exp. Metastasis. 28, 493–503 (2011)PubMedPubMedCentralCrossRef
21.
Y. Suehara, D. Alex, A. Bowman et al., Clinical genomic sequencing of Pediatric and Adult Osteosarcoma reveals distinct molecular subsets with potentially targetable alterations. Clin. Cancer Res. 25, 6346–6356 (2019)PubMedPubMedCentralCrossRef
22.
D. Wang, X. Niu, Z. Wang et al., Multiregion sequencing reveals the genetic heterogeneity and evolutionary history of Osteosarcoma and Matched Pulmonary metastases. Cancer Res. 79, 7–20 (2019)PubMedCrossRef
23.
K. Mulder, A.A. Patel, W.T. Kong et al., Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity. 54, 1883–1900 (2021). e1885PubMedCrossRef
24.
I. Tirosh, B. Izar, S.M. Prakadan et al., Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 352, 189–196 (2016)PubMedPubMedCentralCrossRef
25.
H.W. Lee, W. Chung, H.O. Lee et al., Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 12, 47 (2020)PubMedPubMedCentralCrossRef
26.
M.Z. Noman, M. Hasmim, A. Lequeux et al., Improving Cancer Immunotherapy by targeting the hypoxic Tumor Microenvironment: New opportunities and challenges. Cells, 8 (2019)
27.
I. Corre, F. Verrecchia, V. Crenn et al., The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem, Cells, 9 (2020)
28.
C. Hu, C. Liu, S. Tian et al., Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients. BMC cancer. 20, 814 (2020)PubMedPubMedCentralCrossRef
29.
C. Zhang, J.H. Zheng, Z.H. Lin et al., Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma. Aging. 12, 3486–3501 (2020)PubMedPubMedCentralCrossRef
30.
Y. Han, W. Guo, T. Ren et al., Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis. Cancer Lett., 440–441 116–125 (2019)
31.
K. Wolf-Dennen, N. Gordon, E.S. Kleinerman, Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. Oncoimmunology. 9, 1747677 (2020)PubMedPubMedCentralCrossRef
32.
P. Dhupkar, N. Gordon, J. Stewart et al., Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med. 7, 2654–2664 (2018)PubMedPubMedCentralCrossRef
33.
Q.K. Yang, Y.N. Su, W. Wang et al., CONUT score or/and peripheral blood CD4+/CD8 + ratio-based web dynamic nomograms to predict the individualized survival of patients with Advanced Osteosarcoma. Cancer Manag Res. 12, 4193–4208 (2020)PubMedPubMedCentralCrossRef
34.
Y. Yang, W. Kang, Y. Yuan et al., circ-0007707/miR-429/PDGFD Pathway Regulates the Progression of Gastric Cancer by Modulating the Immune-Gene Signature, J. Oncol., 2022 2214686 (2022)
35.
K. Mu, J. Fu, J. Gai et al., Genetic alterations in the neuronal development genes are associated with changes of the tumor immune microenvironment in pancreatic cancer. Ann. Pancreat. Cancer, 6 (2023)
36.
K. Jin, S. Qiu, D. Jin et al., Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database. Aging (Albany NY). 13, 1859–1871 (2021)PubMedCrossRef
37.
J. Hu, L. Wang, L. Li et al., A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database. BMC Cancer. 22, 1158 (2022)PubMedPubMedCentralCrossRef
38.
X. Gao, J. Yang, Y. Chen, Identification of a four immune-related genes signature based on an immunogenomic landscape analysis of clear cell renal cell carcinoma. J. Cell. Physiol. 235, 9834–9850 (2020)PubMedCrossRef
39.
L. He, H. Yang, J. Huang, The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma. BMC Cancer. 21, 581 (2021)PubMedPubMedCentralCrossRef
40.
W.J. LaRochelle, M. Jeffers, W.F. McDonald et al., PDGF-D, a new protease-activated growth factor. Nat. Cell. Biol. 3, 517–521 (2001)PubMedCrossRef
41.
X. Li, U. Eriksson, Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor. Rev. 14, 91–98 (2003)PubMedCrossRef
42.
E. Bergsten, M. Uutela, X. Li et al., PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat. Cell. Biol. 3, 512–516 (2001)PubMedCrossRef
43.
M. Cadamuro, S. Brivio, J. Mertens et al., Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J. Hepatol. 70, 700–709 (2019)PubMedCrossRef
44.
D. Kong, S. Banerjee, W. Huang et al., Mammalian target of rapamycin repression by 3,3’-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res. 68, 1927–1934 (2008)PubMedPubMedCentralCrossRef
45.
C.V. Ustach, M.E. Taube, N.J. Jr. Hurst et al., A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res. 64, 1722–1729 (2004)PubMedPubMedCentralCrossRef
46.
S. Sethi, F.H. Sarkar, Q. Ahmed et al., Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol. 4, 222–226 (2011)PubMedPubMedCentralCrossRef
47.
J. Liu, S. Liao, Y. Huang et al., PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin. Cancer Res. 17, 3638–3648 (2011)PubMedPubMedCentralCrossRef
48.
J. Li, X. Zhi, Y. Sun et al., The PDGF Family Is Associated with Activated Tumor Stroma and Poor Prognosis in Ovarian Cancer, Dis. Markers, 2022 5940049 (2022)
49.
R.S. Olsen, J. Dimberg, R. Geffers et al., Possible role and therapeutic target of PDGF-D signalling in Colorectal Cancer. Cancer Invest. 37, 99–112 (2019)PubMedCrossRef
50.
H. Zhang, J.D. Sun, L.J. Yan et al., PDGF-D/PDGFRbeta promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway. Biochem. Biophys. Res. Commun. 478, 845–851 (2016)PubMedCrossRef
51.
L. Xu, R. Tong, D.M. Cochran et al., Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res. 65, 5711–5719 (2005)PubMedCrossRef
52.
53.
E. Borkham-Kamphorst, P. Alexi, L. Tihaa et al., Platelet-derived growth factor-D modulates extracellular matrix homeostasis and remodeling through TIMP-1 induction and attenuation of MMP-2 and MMP-9 gelatinase activities. Biochem. Biophys. Res. Commun. 457, 307–313 (2015)PubMedCrossRef
54.
M. Uutela, M. Wirzenius, K. Paavonen et al., PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood. 104, 3198–3204 (2004)PubMedCrossRef
55.
S. Ma, T. Tang, X. Wu et al., PDGF-D-PDGFRbeta signaling enhances IL-15-mediated human natural killer cell survival. Proc. Natl. Acad. Sci. U S A, 119 (2022)
56.
M. Brahmi, T. Lesluyes, A. Dufresne et al., Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas. ESMO Open. 6, 100037 (2021)PubMedPubMedCentralCrossRef
57.
M. Ehnman, E. Missiaglia, E. Folestad et al., Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res. 73, 2139–2149 (2013)PubMedPubMedCentralCrossRef
58.
J.H. McCarty, MMP9 clears the way for metastatic cell penetration across the blood-brain barrier. Cancer Res. 83, 1167–1169 (2023)PubMedCrossRef
59.
J.P. Thiery, Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer. 2, 442–454 (2002)PubMedCrossRef
60.
R. Roy, J. Yang, M.A. Moses, Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27, 5287–5297 (2009)PubMedPubMedCentralCrossRef
61.
M.H. Lu, M.F. Fan, X.D. Yu, NSD2 promotes osteosarcoma cell proliferation and metastasis by inhibiting E-cadherin expression. Eur. Rev. Med. Pharmacol. Sci. 21, 928–936 (2017)PubMed
62.
W. Liu, R.H. Qiao, D.M. Wang et al., UHRF1 promotes human osteosarcoma cell invasion by downregulating the expression of E–cadherin in an Rb1–dependent manner. Mol. Med. Rep. 13, 315–320 (2016)PubMedCrossRef
63.
H. Yang, Y. Zhang, Z. Zhou et al., Transcription factor Snai1-1 induces osteosarcoma invasion and metastasis by inhibiting E-cadherin expression. Oncol. Lett. 8, 193–197 (2014)PubMedPubMedCentralCrossRef
64.
Q. Yuan, H. Yu, J. Chen et al., ADAM10 promotes cell growth, migration, and invasion in osteosarcoma via regulating E-cadherin/beta-catenin signaling pathway and is regulated by miR-122-5p. Cancer Cell. Int. 20, 99 (2020)PubMedPubMedCentralCrossRef
65.
W.H. Lin, L.M. Cooper, P.Z. Anastasiadis, Cadherins and catenins in cancer: connecting cancer pathways and tumor microenvironment. Front. Cell. Dev. Biol. 11, 1137013 (2023)PubMedPubMedCentralCrossRef
66.
67.
68.
H. Wensman, H. Goransson, K.J. Leuchowius et al., Extensive expression of craniofacial related homeobox genes in canine mammary sarcomas. Breast Cancer Res. Treat. 118, 333–343 (2009)PubMedCrossRef
69.
A. Shen, Y. Zhang, H. Yang et al., Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma. J. Surg. Oncol. 105, 830–834 (2012)PubMedCrossRef
Metadata
Title
Exploring the impact of PDGFD in osteosarcoma metastasis through single-cell sequencing analysis
Authors
Yujing Huang
Dongyan Cao
Manxue Zhang
Yue Yang
Gengming Niu
Lina Tang
Zan Shen
Zhichang Zhang
Yueqing Bai
Daliu Min
Aina He
Publication date
23-04-2024
Publisher
Springer Netherlands
Published in
Cellular Oncology
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-024-00949-3
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits